title: Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis.
abstract: Clinical evidence indicates that bone status is affected in patients with type 2 diabetes mellitus (T2DM). Regardless of normal or even high bone mineral density, T2DM patients have increased risk of fractures. One class of antidiabetic drugs, thiazolidinediones (TZDs), causes bone loss and further increases facture risk, placing TZDs in the category of drugs causing secondary osteoporosis. Risk factors for development of TZD-induced secondary osteoporosis are gender (women), age (elderly), and duration of treatment. TZDs exert their antidiabetic effects by activating peroxisome proliferator-activated receptor-γ (PPAR-γ) nuclear receptor, which controls glucose and fatty acid metabolism. In bone, PPAR-γ controls differentiation of cells of mesenchymal and hematopoietic lineages. PPAR-γ activation with TZDs leads to unbalanced bone remodeling: bone resorption increases and bone formation decreases. Laboratory research evidence points toward a possible separation of unwanted effects of PPAR-γ on bone from its beneficial antidiabetic effects by using selective PPAR-γ modulators. This review also discusses potential pharmacologic means to protect bone from detrimental effects of clinically used TZDs (pioglitazone and rosiglitazone) by using combinational therapy with approved antiosteoporotic drugs, or by using lower doses of TZDs in combination with other antidiabetic therapy. We also suggest a possible orthopedic complication, not yet supported by clinical studies, of delayed fracture healing in T2DM patients on TZD therapy.
authors.affiliation: Department of Orthopaedic Surgery, Center for Diabetes and Endocrine Research, University of Toledo Medical Center, OH, 43614, USA. Beata.LeckaCzernik@utoledo.edu
authors.forename: Beata
authors.initials: B
authors.lastname: Lecka-Czernik
mesh_terms: D000818:Animals; D015519:Bone Density / Q000502:physiology; D002454:Cell Differentiation / Q000502:physiology; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use; D010024:Osteoporosis / Q000139:chemically induced* / Q000503:physiopathology / Q000517:prevention & control; D047495:PPAR gamma / Q000037:antagonists & inhibitors; D000077205:Pioglitazone; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D004338:Drug Combinations; D007004:Hypoglycemic Agents; D047495:PPAR gamma; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D000077205:Pioglitazone
references.citation: Am J Epidemiol. 2007 Sep 1;166(5):495-505
references.pmid: 17575306
references.citation: Bone. 2010 Apr;46(4):1138-45
references.pmid: 20044046
references.citation: Arch Intern Med. 2009 Aug 10;169(15):1395-402
references.pmid: 19667303
references.citation: Diabetes Care. 2008 May;31(5):845-51
references.pmid: 18223031
references.citation: JAMA. 2007 Sep 12;298(10):1180-8
references.pmid: 17848652
references.citation: J Clin Endocrinol Metab. 2009 Jul;94(7):2380-6
references.pmid: 19383780
references.citation: Aging Cell. 2004 Dec;3(6):379-89
references.pmid: 15569355
references.citation: Curr Osteoporos Rep. 2010 Jun;8(2):84-90
references.pmid: 20425615
references.citation: CMAJ. 2009 Jan 6;180(1):32-9
references.pmid: 19073651
references.citation: PPAR Res. 2008;2008:520465
references.pmid: 18769492
references.citation: J Cell Biochem. 2009 Feb 1;106(2):232-46
references.pmid: 19115254
references.citation: Am J Manag Care. 2009 Aug;15(8):491-6
references.pmid: 19670952
references.citation: J Clin Endocrinol Metab. 2006 Sep;91(9):3349-54
references.pmid: 16608888
references.citation: N Engl J Med. 2006 Dec 7;355(23):2427-43
references.pmid: 17145742
references.citation: Am J Clin Nutr. 2010 Jan;91(1):267S-272S
references.pmid: 19906796
references.citation: J Clin Endocrinol Metab. 2009 Aug;94(8):2792-8
references.pmid: 19470635
references.citation: Curr Opin Endocrinol Diabetes Obes. 2010 Feb;17(1):44-50
references.pmid: 19907320
references.citation: Endocrinology. 2002 Jun;143(6):2376-84
references.pmid: 12021203
references.citation: J Clin Endocrinol Metab. 2010 Feb;95(2):592-600
references.pmid: 20061432
references.citation: Calcif Tissue Int. 2009 Jan;84(1):45-55
references.pmid: 19067021
references.citation: J Clin Endocrinol Metab. 2010 Jan;95(1):134-42
references.pmid: 19875477
references.citation: Endocrinology. 2004 Jan;145(1):401-6
references.pmid: 14500573
references.citation: Diabetes. 1995 Jul;44(7):775-82
references.pmid: 7789645
references.citation: N Engl J Med. 2004 Sep 9;351(11):1106-18
references.pmid: 15356308
references.citation: Nat Rev Immunol. 2010 May;10(5):365-76
references.pmid: 20414208
references.citation: N Engl J Med. 2007 Jun 14;356(24):2457-71
references.pmid: 17517853
references.citation: PPAR Res. 2007;2007:81219
references.pmid: 18288266
references.citation: Vasc Health Risk Manag. 2007;3(4):503-10
references.pmid: 17969380
references.citation: Diabetes Care. 2002 Oct;25(10):1749-54
references.pmid: 12351472
references.citation: Nat Rev Genet. 2003 Aug;4(8):638-49
references.pmid: 12897775
references.citation: Curr Opin Investig Drugs. 2009 Oct;10(10):1085-90
references.pmid: 19777397
references.citation: Annu Rev Biochem. 2008;77:289-312
references.pmid: 18518822
references.citation: J Biol Chem. 2009 Jul 10;284(28):18767-77
references.pmid: 19423703
references.citation: J Bone Miner Res. 2008 Aug;23(8):1334-42
references.pmid: 18348689
references.citation: J Clin Endocrinol Metab. 2008 Mar;93(3):1013-9
references.pmid: 18160470
references.citation: Croat Med J. 2007 Feb;48(1):87-91
references.pmid: 17309144
references.citation: J Clin Endocrinol Metab. 2008 May;93(5):1696-701
references.pmid: 18285411
references.citation: J Bone Miner Res. 2010 Jun;25(6):1460-2
references.pmid: 19929438
references.citation: Nat Med. 2007 Dec;13(12):1496-503
references.pmid: 18059282
references.citation: J Bone Miner Res. 2005 Sep;20(9):1659-68
references.pmid: 16059637
references.citation: Calcif Tissue Int. 2004 Oct;75(4):329-37
references.pmid: 15549648
references.citation: CMAJ. 2005 Jan 18;172(2):213-26
references.pmid: 15655244
references.citation: J Clin Endocrinol Metab. 2007 Apr;92(4):1305-10
references.pmid: 17264176
references.citation: Arch Intern Med. 2008 Apr 28;168(8):820-5
references.pmid: 18443256
references.citation: J Bone Miner Res. 2009 Apr;24(4):702-9
references.pmid: 19049338
references.citation: Nat Clin Pract Rheumatol. 2006 Jan;2(1):35-43
references.pmid: 16932650
references.citation: PLoS Med. 2009 Sep;6(9):e1000154
references.pmid: 19787025
references.citation: Diabetes Care. 2009 Jul;32(7):1224-30
references.pmid: 19289857
references.citation: Bone. 2006 Jan;38(1):74-84
references.pmid: 16137931
references.citation: J Musculoskelet Neuronal Interact. 2005 Oct-Dec;5(4):316
references.pmid: 16340119
references.citation: Osteoporos Int. 2010 Dec;21(12):2013-8
references.pmid: 20130841
references.citation: Nat Med. 2010 Jun;16(6):614
references.pmid: 20526293
references.citation: Calcif Tissue Int. 2010 May;86(5):343-9
references.pmid: 20354684
references.citation: Endocrinology. 2007 Jun;148(6):2669-80
references.pmid: 17332064